Published customer image:
Horseradish peroxidase conjugated Goat anti Human kappa light chain antibody (STAR127P) used to evaluate Vedolizumab levels in serum by ELISA.
Image caption:
Vedolizumab discontinuation trough levels in association with response to subsequent all non-surgical therapy (a) and anti-TNF therapy (b) at 6 and 12 months post discontinuation. Data presented as median and IQR. TNF—Tumor necrosis factor.

From: Levartovsky A, Cohen I, Abitbol CM, Yavzori M, Fudim E, Picard O, Kopylov U, Ben-Horin S, Ungar B.
Do Vedolizumab trough Levels Predict the Outcome of Subsequent Therapy in Inflammatory Bowel Disease?
Biomedicines. 2023 May 26;11(6):1553.
doi: 10.3390/biomedicines11061553. .
This image is from an open access article distributed under terms of a Creative Commons Attribution License.